LITFULO has already been approved by the U.S. Food and Drug Administration (FDA) and the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of alopecia areata in June this year.

Litfulo is the first FDA-approved treatment for severe alopecia in patients aged as young as 12 years. The approval was based on results from a phase 2b/3 trial recently published in The Lancet.

PFE is currently evaluating Litfulo in an ongoing long-term phase III ALLEGRO-LT study, collecting the safety and efficacy data for adults with alopecia areata with 25% or greater scalp hair loss ...

Litfulo is the first and only FDA-approved treatment for adolescents (12+) with severe alopecia areata. Alopecia areata is a disease when the immune system attacks hair follicles and causes hair loss.

Pfizer’s Litfulo (ritlecitinib) has been approved by the European Commission (EC) to treat adults and adolescents with severe alopecia areata. The decision makes Litfulo the first medicine authorised ...

Pfizer’s Litfulo (ritlecitinib) has been approved by the US Food and Drug Administration (FDA) as the first treatment option for patients aged 12 years and older with severe alopecia areata. Affecting ...

New treatment for teens with alopecia The FDA approved the once-daily pill called Litfulo, created by pharmaceutical giant Pfizer, for people 12 and up to treat severe alopecia areata, or at least ...

This release contains forward-looking information about LITFULO (ritlecitinib), including its potential benefits and an approval by the European Commission to treat adults and adolescents 12 years ...

With the approval of Litfulo in the EU, the drug becomes the first EC-approved medicine to be indicated for adolescent patients, as young as 12 years of age, with severe alopecia areata.

Litfulo is the first and only FDA-approved treatment for adolescents (12+) with severe alopecia areata. Alopecia areata is a disease when the immune system attacks hair follicles and causes hair loss.

Pfizer PFE announced that the FDA approved Litfulo (ritlecitinib) for treating people with severe alopecia areata. The regulatory agency approved the drug as an oral treatment for those aged 12 ...